Disc Medicine, Inc. (IRON) FY2025 10-K Annual Report
Disc Medicine, Inc. (IRON) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Disc Medicine, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: clinical-stage biopharma developing novel treatments targeting red blood cell biology, focusing on heme biosynthesis and iron homeostasis pathways
- • New emphasis: submission of NDA for bitopertin in erythropoietic porphyrias (EPP and XLP) with FDA accelerated approval pursuit, ongoing Phase 3 APOLLO trial initiated May 2025
- • Strategic shift: pivot to address FDA complete response letter by generating Phase 3 data for traditional approval; expanding pipeline into myeloproliferative neoplasms with DISC-0974 and DISC-3405
- • Quantitative highlight: approx. 14,000 diagnosed EPP patients US market; Phase 2 trial of DISC-0974 in myelofibrosis anemia showed anemia responses independent of transfusion or JAK inhibitor use
- • Noteworthy fact: received FDA Commissioner’s National Priority Voucher in October 2025 for bitopertin, highlighting regulatory priority for this rare disease therapy
Management Discussion & Analysis
- • No revenue generated; net loss $212.2M in 2025 vs $109.4M in 2024, loss doubled YoY
- • Operating expenses up $106.3M YoY: R&D $170.6M vs $96.7M, SG&A $65.4M vs $33.0M
- • R&D increase driven by bitopertin ($58.8M, +$30.7M), DISC-0974 ($27.6M, +$10.6M); bitopertin lead program
- • Cash and equivalents $791.2M at end 2025; raised $211.0M net proceeds in Oct 2025 equity offering
- • FDA issued CRL for bitopertin NDA in Feb 2026; APOLLO Phase 3 topline data expected Q4 2026 to support resubmission
Risk Factors
- • Regulatory risk: Dependency on FDA approval timing and conditions for product candidates impacts commercialization and cost structure
- • Macroeconomic threat: Cash runway extends only to 2029 with $791.2M liquidity; accelerated spending could exhaust funds earlier
- • Supply chain vulnerability: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing with some non-cancellable fees
- • Competitive risk: Potential market disruption from approved therapies competing with bitopertin or other pipeline products
- • Financial risk: Accumulated deficit $510.2M with increasing annual net losses ($212.2M in 2025) and heavy equity reliance for funding
Disc Medicine, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$212M
▼ -94.0% YoY
ROE
-28.7%
▼ -403bp YoY
Total Assets
$807M
▲ +62.4% YoY
EPS (Diluted)
$-6.01
▼ -51.8% YoY
Operating Cash Flow
-$180M
▼ -92.1% YoY
Source: XBRL data from Disc Medicine, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Disc Medicine, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.